CTLA4 and COVID-19: The peak observed in 2021 likely reflects a culmination of key drug approvals (e.g., Lenvatinib plus Pembrolizumab) (31), the impact of COVID-19 on scientific output and research direction, and a shift of attention toward novel targets such as CTLA-4 and LAG-3 (33).